Unique ID issued by UMIN | UMIN000006002 |
---|---|
Receipt number | R000007101 |
Scientific Title | Effectiveness of intracoronary bolus abciximab application for patients who suffer from No-Reflow or Slow flow phenomenon during PCI |
Date of disclosure of the study information | 2011/07/19 |
Last modified on | 2018/09/05 11:27:03 |
Effectiveness of intracoronary bolus abciximab application for patients who suffer from No-Reflow or Slow flow phenomenon during PCI
Effectiveness of intracoronary bolus abciximab application for No-Reflow or Slow flow phenomenon during PCI
Effectiveness of intracoronary bolus abciximab application for patients who suffer from No-Reflow or Slow flow phenomenon during PCI
Effectiveness of intracoronary bolus abciximab application for No-Reflow or Slow flow phenomenon during PCI
Japan |
Patients suffer from No-Reflow or Slow flow phenomenon during PCI
Cardiology |
Others
NO
To investigate the effectiveness of intracoronary bolus abciximab application for patients who suffer from No-Reflow or Slow flow phenomenon during PCI
Efficacy
Exploratory
Pragmatic
Not applicable
Rate of attrition of ST elevation ratio :Comparison between at 30 minutes after PCI and at the time of maximum ST elevation
1. Rate of ST re-elevation after intracoronary bolus application of drug(s)
2. TIMI flow after PCI
3. Myocardial blush grade after PCI
4. Maximum value of CPK/CPK-MB after PCI
5. MACCE at 30 days / 1 year after PCI
6. Existence or nonexistence of serious hemorrhagic complication
7. Angiographical phenomenon at follow-up CAG
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
Institution is considered as a block.
NO
Numbered container method
2
Treatment
Medicine |
Abciximab (+)
Abciximab (-)
20 | years-old | <= |
90 | years-old | > |
Male and Female
1. Patients with coronary artery disease
2. Patients who take aspirin and thienopyridine
3. Informed consent was obtained from patients
1.with hemorrhagic diathesis and/or hypercoagulability
2.under emergent PCI
3.received thrombolytic therapy before PCI
4.more than twice the value of standard CPK and CPK-MB
5.be pregnant or nursing
6.with unprotected LMT disease
30
1st name | |
Middle name | |
Last name | Kazuaki Mitsudo |
Kurashiki Central Hospital
Department of Cardiology
Kurashiki city miwa 1-1-1, Okayama, Japan
086-422-0210
1st name | |
Middle name | |
Last name | Daiji Hasegawa |
Kurashiki Central Hospital
Department of Cardiology
Kurashiki city miwa 1-1-1, Okayama, Japan
086-422-0210
dh10969@kchnet.or.jp
Department of Cardiology, Kurashiki Central Hospital
Department of Cardiology, Kurashiki Central Hospital
Self funding
Japan
NO
倉敷中央病院
2011 | Year | 07 | Month | 19 | Day |
Unpublished
Completed
2010 | Year | 07 | Month | 07 | Day |
2011 | Year | 07 | Month | 01 | Day |
2016 | Year | 03 | Month | 11 | Day |
2011 | Year | 07 | Month | 19 | Day |
2018 | Year | 09 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007101
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |